Investors back new biotech with heart disease treatment from China Braveheart Bio raised $185 million to run late-stage trial of a hypertrophic cardiomyopathy medicine

https://www.statnews.com/2025/11/05/investors-back-braveheart-bio-heart-disease-treatment-china/